The OECD is launching an online consultation: tell us how we can improve sustainable access to innovative therapies!
Mental disorders account for one of the largest and fastest growing categories of the burden of disease with which health systems must cope, often accounting for a greater burden than cardiovascular disease and cancer.
The pricing of specialist and hospital services is a contentious issue in South Africa. To help inform domestic debates, the OECD Secretariat has produced a paper profiling international experiences on the pricing of specialist medical services services, competition policy and models of buying services from the private sector.
This document outlines the methodologies and tools currently used to assess the risk of chemicals to children’s health and also identifies possible needs for additional guidance or tools based on the results of an on-line survey conducted in November 2011. The following areas of risk assessment are covered: definitions, hazard and exposure assessment, risk characterisation, cohort studies and combined exposure to multiple chemicals.
English, , 429kb
This guide comprises eight key points for planning public engagement activities. It contains a set of questions to help policy makers develop a plan from start to finish, as well as practical case studies from countries that have used the guide in their communication activities.
The Recommendation seeks to assist both OECD member and non-member countries in the development of appropriate sustainability assessment methodologies for bio-based products.
English, , 287kb
The aim of these guidelines is to propose a harmonised approach for the collection and analysis of biotechnology research and development (R&D) statistics in the government and higher education sectors.
The ability to effectively use these vast amounts of knowledge will depend in part on the bringing together of different strands of information, data and biological materials within human biobanks and genetic research databases (HBGRDs).
Genetics is playing an increasingly important role in health care. New technical advances and information deriving from human genome research are changing health care practices and the economics of healthcare provision.
This report presents the outcome of discussions held by the OECD member countries, together with a number of key partner countries, under the auspices of an expert Task Force established by the OECD Working Party on Biotechnology.